FDA approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
August 17, 2020 – Roche (Basel, Switzerland) announced that the U.S. Food and Drug Administration (FDA) has approved ENSPRYNG (satralizumab-mwge) as the first and only…